Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis

Abstract The HER2-directed antibody-drug conjugate trastuzumab deruxtecan is active against lower levels of HER2 expression than prior-generation therapies. The rate of HER2 expression in brain metastases among patients with initially HER2-null breast cancer is undefined, and receptor discordance in...

Полное описание

Библиографические подробности

Главные авторы:	Nelson S. Moss, Jolene M. Singh, Anne S. Reiner, Joshua Z. Drago, Shanu Modi, Andrew D. Seidman, Sarat Chandarlapaty, Dara S. Ross
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Nature Portfolio 2023-10-01
Серии:	npj Breast Cancer
Online-ссылка:	https://doi.org/10.1038/s41523-023-00592-5
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!